Peptides
PharmaTher believes that delivery innovation—including patient-friendly administration and differentiated pharmacokinetic profiles—can be an important value driver for peptide programs, particularly in chronic conditions where persistence and convenience matter.
Initial Peptide Candidates Under Evaluation
As part of its peptide initiative, PharmaTher is seeking to investigate PharmaPatch™ delivery feasibility for certain peptides, including:
The Company emphasizes that these candidates are being evaluated within a staged R&D framework and that any potential future development pathways will be assessed in alignment with applicable regulatory requirements.
Initial Peptide Candidates Under Evaluation
As part of its peptide initiative, PharmaTher is seeking to investigate PharmaPatch™ delivery feasibility for certain peptides, including:
- BPC-157
- GHK-Cu (copper tripeptide-1)
- TB-500 (Thymosin Beta-4 fragment)
- KPV (Lys-Pro-Val)
- Potential combinations of the above peptides
The Company emphasizes that these candidates are being evaluated within a staged R&D framework and that any potential future development pathways will be assessed in alignment with applicable regulatory requirements.
© COPYRIGHT 2026. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."